A. Baños

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

Delphine Rossille, M Gréssier, Diane Damotte et al. · Leukemia · 2014 · 324 citations

Medicine, Hematology, Oncology +14

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret et al. · Leukemia · 2015 · 121 citations · Full text

Medicine, Hematology, Pharmacotherapy +9

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Meletios Α. Dimopoulos, K. Weisel, Kevin Song et al. · Haematologica · 2015 · 72 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Jesús F. San Miguel, K. Weisel, Kevin Song et al. · Haematologica · 2015 · 52 citations · Full text

Medicine, Hematology, Pharmacology +14

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

Gandhi Damaj, Florent Malard, Cyrille Hulin et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 44 citations

Medicine, Oncology, Pharmacology +13